Cerevel Therapeutics Reports Positive Topline Results From Phase 1b Clinical Trial Of New Schizophrenia Medication

Cerevel Therapeutics Holdings Inc. reported positive results from its Phase 1b clinical trial of CVL-231, a novel muscarinic M4-selective positive allosteric modulator, in adults with schizophrenia. The medication was tested at two doses (30 mg once-daily and 20 mg twice-daily) for six weeks and compared to a placebo. Both doses demonstrated clinically meaningful antipsychotic activity.

The CVL-231 30 mg once-daily dose resulted in a statistically significant and clinically meaningful mean reduction from baseline of 19.5 points in the Positive and Negative Syndrome Scale total score and a mean reduction of 12.7 points . . .